{"nctId":"NCT01307579","briefTitle":"Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia","startDateStruct":{"date":"2011-04-04","type":"ACTUAL"},"conditions":["Acute Myeloid Leukemia","Adult Acute Monoblastic Leukemia","Adult Acute Monocytic Leukemia","Adult Acute Myeloid Leukemia in Remission","Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11","Adult Acute Myeloid Leukemia With Maturation","Adult Acute Myeloid Leukemia With Minimal Differentiation","Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11","Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1","Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A","Adult Acute Myeloid Leukemia Without Maturation","Adult Acute Myelomonocytic Leukemia","Alkylating Agent-Related Acute Myeloid Leukemia","Childhood Acute Monoblastic Leukemia","Childhood Acute Monocytic Leukemia","Childhood Acute Myeloid Leukemia in Remission","Childhood Acute Myeloid Leukemia With Maturation","Childhood Acute Myeloid Leukemia With Minimal Differentiation","Childhood Acute Myeloid Leukemia Without Maturation","Childhood Acute Myelomonocytic Leukemia","Fungal Infection","Myeloid Neoplasm","Neutropenia","Recurrent Adult Acute Myeloid Leukemia","Recurrent Childhood Acute Myeloid Leukemia","Secondary Acute Myeloid Leukemia","Untreated Adult Acute Myeloid Leukemia","Untreated Childhood Myeloid Neoplasm"],"count":517,"armGroups":[{"label":"Arm I (caspofungin acetate)","type":"EXPERIMENTAL","interventionNames":["Drug: Caspofungin Acetate","Other: Laboratory Biomarker Analysis"]},{"label":"Arm II (fluconazole)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Fluconazole","Other: Laboratory Biomarker Analysis"]}],"interventions":[{"name":"Caspofungin Acetate","otherNames":["Cancidas"]},{"name":"Fluconazole","otherNames":["Diflucan"]},{"name":"Laboratory Biomarker Analysis","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients must have one of the following diagnoses and/or treatment plans:\n\n  * Newly diagnosed de novo AML\n  * First or subsequent relapse of AML\n  * Secondary AML\n  * Treatment with institutional standard AML therapy in those without AML (for example, myelodysplastic syndrome, bone marrow blasts \\> 5% or biphenotypia)\n  * Note: Patients with a history of prolonged antifungal therapy (example, relapsed AML) are eligible\n* Creatinine clearance or radioisotope glomerular filtration rate (GFR) \\>= 70 mL/min/1.73 m\\^2 OR a serum creatinine based on age/gender as follows:\n\n  * =\\< 0.4 mg/dL (age 1 month to \\< 6 months)\n  * =\\< 0.5 mg/dL (age 6 months to \\< 1 year)\n  * =\\< 0.6 mg/dL (age 1 to \\< 2 years)\n  * =\\< 0.8 mg/dL (age 2 to \\< 6 years)\n  * =\\< 1 mg/dL (age 6 to \\< 10 years)\n  * =\\< 1.2 mg/dL (age 10 to \\< 13 years)\n  * =\\< 1.4 mg/dL (females age \\>= 13 years)\n  * =\\< 1.5 mg/dL (males age 13 to \\< 16 years)\n  * =\\< 1.7 mg/dL (males age \\>= 16 years)\n* Total bilirubin =\\< 1.5 x upper limit of normal (ULN) for age AND Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase \\[AST\\]) or serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase \\[ALT\\]) \\< 2.5 x ULN for age\n* All patients and/or their parents or legal guardians must sign a written informed consent\n\nExclusion Criteria:\n\n* Patients with the following diagnoses are not eligible:\n\n  * Acute promyelocytic leukemia (APL)\n  * Down syndrome\n  * Juvenile myelomonocytic leukemia (JMML)\n* Patients with a documented history of invasive fungal infection (IFI) within the previous 30 days are not eligible\n* Patients with a history of echinocandin or fluconazole hypersensitivity are not eligible\n* Patients receiving treatment for an IFI are not eligible\n* Female patients of childbearing age must have a negative pregnancy test\n* Patients must agree to use an effective birth control method\n* Lactating patients must agree not to nurse a child while on this trial","healthyVolunteers":false,"sex":"ALL","minimumAge":"3 Months","maximumAge":"30 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Proven or Probable Invasive Fungal Infections (IFI)","description":"Proven or probable IFI is defined according to criteria developed by the European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":null},{"groupId":"OG001","value":"7.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Proven or Probable Invasive Aspergillosis (IA)","description":"Proven or probable invasive aspergillosis (IA) is defined according to the criteria developed by the EORTC/MSG. Kaplan Meier approach will used to estimate the incidence.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"3.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Kaplan Meier method will be used to estimate overall survival. Time to event is from enrollment to date of death (by any cause). Participants are censored at last contact or 2 years anniversary of enrollment into this study, whichever occurred first.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.8","spread":null},{"groupId":"OG001","value":"70.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants That Need Empiric Antifungal Therapy","description":"The percentage of participants requiring empiric antifungal therapy will be determined based on the presence of prolonged fever and neutropenia during each neutropenia course.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.9","spread":null},{"groupId":"OG001","value":"69.5","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Sensitivity of Galactomannan and Beta-D Glucan Assays for the Diagnosis of Proven or Probable IFI","description":"Sensitivity for the diagnosis of proven or probable IFI will be determined for the fungal biomarkers galactomannan and beta-D glucan assays. Sensitivity will be estimated for the combination of the two fungal biomarkers.","paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Specificity of Galactomannan and Beta-D Glucan Assays for the Diagnosis of Proven or Probable IFI","description":"Specificity of galactomannan and beta-D glucan assays for the diagnosis of proven or probable IFI. Specificity will be estimated for the two fungal biomarkers together.","paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Positive Predictive Value of Galactomannan and Beta-D Glucan Assays for the Diagnosis of Proven or Probable IFI","description":"Positive predictive value of galactomannan and beta-D glucan assays for the diagnosis of proven or probable IFI. Positive predictive value will be estimated for the two fungal biomarkers together.","paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Negative Predictive Value of Galactomannan and Beta-D Glucan Assays for the Diagnosis of Proven or Probable IFI","description":"Negative predictive value of galactomannan and beta-D glucan assays for the diagnosis of proven or probable IFI. Negative predictive value will be estimated for the two fungal biomarkers together.","paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Genotyping Assays for Single Nucleotide Polymorphism Analysis","description":"Descriptive statistics will be used to summarize the prevalence of single nucleotide polymorphisms.","paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":253},"commonTop":["Sepsis","Hypokalemia","Hypotension","Infections and infestations - Other, specify","Respiratory failure"]}}}